Xin-Yao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin-Yao Zhang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Huai-Qiang Ju
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
20 shared publications - Rui-Hua Xu
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
20 shared publications - Zhao-Lei Zeng
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
20 shared publications - BaoQing Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
19 shared publications - Chiu-Wing Yeung
Sun Yat-sen University Cancer Center 1 Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Guangzhou, P. R. China
19 shared publications - Hao-Jie Chen
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
19 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S7 Dynamic metabolite model construction and performance evaluation
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S7 Dynamic metabolite model construction and performance evaluation
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S5 Identification of optimal long PFS cutoff to distinguish long and short term responders and key metabolite differences and predictive performance of on-treatment model
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S5 Identification of optimal long PFS cutoff to distinguish long and short term responders and key metabolite differences and predictive performance of on-treatment model
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S3 Baseline metabolite model performance validation and clinical prognostic analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S3 Baseline metabolite model performance validation and clinical prognostic analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S2 Metabolic block construction and validation analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S2 Metabolic block construction and validation analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S4 TG pattern shifts from baseline to on-treatment
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S4 TG pattern shifts from baseline to on-treatment
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to chemoimmunotherapy, with only a minority achieving durable benefit, necessitating dynamic precision monitoring. Through longitudinal plasma metabolomics of 541 serial samples from 252 ESCORT-1st trial patients receiving chemoimmunotherapy plus 3 independent cohorts of 288 samples, we established an integrated risk assessment framework spanning the entire therapeutic continuum: (i) a baseline predictor for initial responders based on metabolite signatures; (ii) an on-treatment predictor in prognosticating long-term responders among initial ones based on treatment-induced metabolic shift patterns; and (iii) a real-time model based on dual alteration of sphingolipid and glycerophospholipid dynamically stratifying progression risk. Meanwhile, 2 dietary metabolites, garlic-derived S-allyl-L-cysteine and cruciferous vegetable–derived indole-3-carbinol, were confirmed to improve outcomes by promoting NK-cell infiltration and reversing CD8+ T-cell exhaustion. In conclusion, we provide the first metabolomic roadmap for precision chemoimmunotherapy in ESCC, unifying baseline prediction, longitudinal surveillance, and dietary modulation into a clinically actionable paradigm.Significance:We established a large-scale plasma metabolomic database from patients with ESCC undergoing chemoimmunotherapy, defining the first noninvasive, comprehensive, and precise monitoring framework for treatment response prediction and risk assessment. Our findings reveal clinically actionable dietary metabolites that may serve as readily accessible adjuvants to enhance chemoimmunotherapy efficacy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Esophageal squamous cell carcinoma (ESCC) exhibits heterogeneous responses to chemoimmunotherapy, with only a minority achieving durable benefit, necessitating dynamic precision monitoring. Through longitudinal plasma metabolomics of 541 serial samples from 252 ESCORT-1st trial patients receiving chemoimmunotherapy plus 3 independent cohorts of 288 samples, we established an integrated risk assessment framework spanning the entire therapeutic continuum: (i) a baseline predictor for initial responders based on metabolite signatures; (ii) an on-treatment predictor in prognosticating long-term responders among initial ones based on treatment-induced metabolic shift patterns; and (iii) a real-time model based on dual alteration of sphingolipid and glycerophospholipid dynamically stratifying progression risk. Meanwhile, 2 dietary metabolites, garlic-derived S-allyl-L-cysteine and cruciferous vegetable–derived indole-3-carbinol, were confirmed to improve outcomes by promoting NK-cell infiltration and reversing CD8+ T-cell exhaustion. In conclusion, we provide the first metabolomic roadmap for precision chemoimmunotherapy in ESCC, unifying baseline prediction, longitudinal surveillance, and dietary modulation into a clinically actionable paradigm.Significance:We established a large-scale plasma metabolomic database from patients with ESCC undergoing chemoimmunotherapy, defining the first noninvasive, comprehensive, and precise monitoring framework for treatment response prediction and risk assessment. Our findings reveal clinically actionable dietary metabolites that may serve as readily accessible adjuvants to enhance chemoimmunotherapy efficacy.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 6: Prediction Result of On-Treatment Metabolite Model for Long-Term Responder
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 6: Prediction Result of On-Treatment Metabolite Model for Long-Term Responder
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S6 Time-dependent metabolic risk analysis and lipid subtype characterization
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Figure S6 Time-dependent metabolic risk analysis and lipid subtype characterization
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 1: Basic Clinical Information of Patients collected from the ESCORT-1st trial
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 1: Basic Clinical Information of Patients collected from the ESCORT-1st trial
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 4: Basic Clinical Information of Patients from External Test Cohort 3
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy
Supplementary Table 4: Basic Clinical Information of Patients from External Test Cohort 3